Agnitio Microfluidic Technology and Microarray Technology Platform has been Approved for Marketing under Class III In-Vitro Diagnostic Reagents of Chi
June 15, 2015.
Agnitio Science and Technology, Inc. (Agnitio) was established in Science Park, Hsinchu, in 2001. The company has successfully developed BioIC®, a microfluidic technology and microarray technology platform, by integrating microfluidic driving technology, microarray technology, image analysis process, and surface treatment technology. This product has made chip system practical and valuable in clinical diagnosis through applications in allergen detection product generation and relevant diagnostic bio-indicators. After years of research and developments, as well as expanding market distribution channels of private brand, the product have successfully entered the international market of advanced in-vitro diagnostic reagents and opened a way for Taiwanese biotechnology.
The BioIC® Allergen Specific-IgE Detection Kit has been marketed for many years in Taiwan, with product quality and efficiency being verified over time. It has become a nationwide indicator for many allergen detections and testing. Moreover, BioIC® has been certified in uprising members of the Association of Southeast Asia Countries such as Malaysia, Indonesia, Vietnam, etc. It has performed well in expending distribution channels, and is proactively preparing for the European and Central Asia markets.
In mainland China, the second largest economy in the world and the largest medical equipment market in Asia, the allergen detection system has completed clinical trials and been authorized to market by the China Food and Drug Administration (CFDA) after many years of hard work by Angitio. Angitio’s microfluidic technology and microarray technology platform (BioIC®) is the system with the most detecting items of allergens authorized to market in China. It also has advantage in an oligopoly of automatic detection system of allergens, the multi-allergen detection, together with equipment support of flexible combinations and experienced distribution partner, SKR Investments Limited, looks essentially to be competitive in vast Chinese market.
Jerry Tsai, the General Manager of Agnitio, commented that the company would start implementing profit and growth model following the authorization by CFDA and consolidating overall revenues in expectations to return to profit in next year with a substantial revenue growth.
